|Bid||78.72 x 800|
|Ask||84.99 x 900|
|Day's Range||77.25 - 80.50|
|52 Week Range||77.25 - 186.82|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||232.67|
Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.
Ladies and gentlemen, thank you for standing by, and welcome to the Reata Pharmaceuticals' First Quarter 2021 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call today on Reata's website at reatapharma.com in the Investors section.
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 14.68% and -32.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?